and Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN (M.J.A.). The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/Rationale: Most cardiac ryanodine receptor (RyR2) mutations associated with catecholaminergic polymorphic ventricular tachycardia (CPVT) are postulated to cause a distinctive form of Ca 2+ release dysfunction. Considering the spread distribution of CPVT mutations, we hypothesized that dysfunctional heterogeneity also was feasible.
T ype 2 ryanodine receptors (RyR2s) are the calcium release channels of sarcoplasmic reticulum (SR) that provide the majority of calcium ions (Ca 2+ ) necessary to induce contraction of cardiac cells. 1 In their intracellular environment, RyRs are regulated by a variety of cytosolic and luminal factors so that their output signal (Ca 2+ ) induces finely graded cell contraction without igniting cellular processes that may lead to aberrant electric activity (ventricular arrhythmias). 2 The importance of RyR2 dysfunction has been recently highlighted with the demonstration that point mutations in RYR2, the gene encoding RyR2 channels, are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), an arrhythmogenic syndrome characterized by the development of adrenergically mediated ventricular tachycardia (VT) in individuals with an apparently normal heart. 3 Equivalent mutations engineered in the murine RyR2 gene also result in the development of phenotypes that recapitulate the major clinical manifestations of CPVT. Hence, CPVT mice represent a bona fide experimental model in which the role of deranged Ca 2+ homeostasis in the triggering of arrhythmias (Ca 2+ -dependent arrhythmogenesis) may be integrally assessed. However, the molecular mechanisms that link a mutation in the RyR2 protein and the development of tachyarrhythmia remain incompletely understood.
To date, a considerable number of single amino acid RyR2 mutations (>150) have been associated with the development of CPVT (http://www.fsm.it/cardmoc). 4 Remarkably, the majority of these mutations 3 fall within 3 loci (hot spots), termed CPVT-I, CPVT-II, and CPVT-III domains, of the RyR2 protein, which are involved in several aspects of RyR2 regulation. Yet, most CPVT mutations characterized to date display a single mechanism of RyR2 dysfunction. [5] [6] [7] [8] [9] [10] [11] [12] This stereotyped mechanism of dysfunction is puzzling, given the multiple functional domains of the RyR2 protein potentially affected by each of the CPVT mutations. Furthermore, CPVT episodes, by definition, occur after acute β-adrenergic stimulation, but it is unknown whether phosphorylation of RyR2 channels is an obligatory step to elicit abnormal Ca 2+ release in mutant channels or whether sympathetic stimulation only exacerbates the activity of an RyR2 channel already on the verge of ignition.
We performed an in-depth characterization of a novel CPVT-linked mutation, RyR2-V2475F, that was identified postmortem in a case of unexplained drowning of a young boy. 13 The mutation falls within the canonical CPVT-II domain but, unlike other RyR2 mutants, RyR2-V2475F displays multiple mechanisms of RyR2 dysfunction, including increased cytosolic Ca 2+ sensitivity, altered SR calcium concentration ([Ca 2+ ] luminal ) regulation, and abnormal response to protein kinase A (PKA) phosphorylation. In vivo, the RyR2-V2475F mutation is highly arrhythmogenic. Thus, the RyR2-V2475F mutation produces a heterogeneous mechanism of RyR2 dysfunction.
Methods
Recombinant mutant channels were generated by site-directed mutagenesis, expressed in human embryonic kidney (HEK) 293 cells, and purified as described. 5 Mice with the RyR2-V2475F mutation were generated by homologous recombination. RyR2-V2475F +/− mice and age-matched wild-type (WT) littermates were maintained and studied according to the protocol approved by the Institutional Animal Care and Use Committees of the University of Wisconsin-Madison and the University of Michigan-Ann Arbor and by the Association for Assessment and Accreditation of Laboratory Care International. An expanded Methods section is available in the Online Data Supplement.
Results

Expression and Characterization of Recombinant RyR2-V2475F Channels
RyR2 mutations associated with CPVT cluster in 3 welldefined domains that control different aspects of channel function. Because these canonical domains are well-conserved among species, we used site-directed mutagenesis to introduce in the mouse RYR2 gene several mutations that are associated with CPVT in humans. The RyR2 mutations R176Q and R414C (pertaining to CPVT-I), V2475F (pertaining to CPVT-II), and G4671C (pertaining to CPVT-III) were expressed as described in Methods. We first tested their sensitivity to activation by Ca 2+ using tritiated ryanodine ([ 3 H] ryanodine) binding assays. [ 3 H]Ryanodine is a conformationally sensitive ligand that binds to the open state of RyRs and may be used as a reliable index of the activity of the channel. Figure 1A shows the Ca 2+ dependence of [3H]ryanodine binding of purified WT (control) and mutant channels. For all channels, calcium concentration ([Ca 2+ ]) threshold for activation was above pCa 8 and reached plateau at pCa ≈5. The activation was sigmoidal and could be fitted with a Hill equation, with EC 50 =pCa 6.3±0.12 for WT, R176Q, R414C, and G4671 channels. Remarkably, only V2475F displayed significant difference with WT, with EC 50 =6.8±0.15. At pCa 7, activation of WT channels was only ≈10% of normalized value, whereas in V2475F activation exceeded ≈40%. Because previous work has demonstrated that Ca 2+ in the range of 100 nmol/L (pCa 7) to 10 µmol/L (pCa 5) binds to a high-affinity Ca 2+ -binding site in the cytosolic portion of the RyR protein, 2,5,6 the results suggest that the V2475F mutation confers RyR2 channel hypersensitivity to cytosolic Ca 2+ . Mutations that alter RyR2 activity at pCa 7 are especially interesting because this is the basal [Ca 2+ ] reached during diastole.
To directly test whether the V2475F mutation increased the sensitivity of the RyR2 channel to cytosolic Ca 2+ , we reconstituted purified WT and V2475F channels in planar lipid bilayers. 14 Figure 1B shows single-channel activity at the indicated cis (cytosolic) [Ca 2+ ], and current histograms of cumulative recordings performed in 6 WT and 4 V2475F channels are also shown in Figure 1B 
PKA Phosphorylation Exacerbates the Hypersensitivity of V2475F Channels to Cytosolic Ca 2+
Tachyarrhythmia in CPVT is triggered by physical exercise or anxiety, in other words, during sympathetic stimulation. 3, 15 Sympathetic stimulation of the heart triggers the β-adrenergic cascade, which activates protein kinases. 1, 2 We tested the effect of PKA and calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylation on recombinant WT and V2475F channels. Figure 2A shows Western blots of WT and V2475F channels before (control and after (+PKA) incubation with the catalytic subunit of PKA (1 µg/mL). Antibodies used were anti-RyR2, which detected total protein, and the phosphorylationsensitive anti-pS2808 (PKA and CaMKII site), anti-pS2030 (PKA site), and anti-pS2814 (CaMKII site). 16 As expected, PKA phosphorylation of WT and V2475F channels did not change the band intensity of anti-RyR2 or anti-pS2814 and increased the phospho-signal of anti-pS2808 and anti-pS2030. However, V2475F channels were less sensitive to S2808 phosphorylation and more sensitive to S2030 phosphorylation with respect to WT ( Figure 2B ). We next tested whether the differential phosphorylation of V2475F channels had a functional correlate. We repeated the Ca 2+ dependence of [3H] ryanodine-binding experiments using the PKA-treated WT and V2475F channels. PKA phosphorylation did not change significantly the sensitivity of WT channels (EC 50 =6.4±0.14) but exaggerated the already abnormal sensitivity of V2475F for cytosolic Ca 2+ (EC 50 =7.1±0.16; Figure 2C ). In contrast, we did not detect differential CaMKII phosphorylation of S2808 or S2814 (S2030 was not responsive to CaMKII, as expected) or changes in [ 3 H]ryanodine binding after CaMKII phosphorylation (Online Figure I) . These results suggest that PKA Figure 1 . Cardiac ryanodine receptor (RyR2)-V2475F channels display higher sensitivity to cytosolic Ca 2+ than wild-type (WT) channels. A, Ca 2+ dependence of tritiated ryanodine ([ 3 H]ryanodine) binding curves performed in parallel using the solubilized and purified channels is indicated in the inset. *P<0.05. B, Single-channel recordings of WT and V2475F channels reconstituted in lipid bilayers. Left, Two-second segments of representative single-channel activity at the indicated cis (cytosolic) Ca 2+ . Right, Current histograms of at least 5 minutes of cumulative recording performed in 6 (WT) and 4 (V2475F) channels.
Figure 2. Protein kinase A (PKA) phosphorylation increases the sensitivity of V2475F channels to cytosolic Ca 2+ . A,
Western blots of wild-type (WT) and V2475F channels before (control) and after (+PKA) incubation with the catalytic subunit of PKA. Antibodies used were anti-RyR2 (1:3000), anti-pS2809 (1:1 0000), anti-pS2030 (1:10 000), and anti-pS2814 (1:10 000). B, Average band intensity (normalized to total cardiac ryanodine receptor [RyR2] protein) of 4 independent determinations with the indicated antibodies. C, Ca 2+ dependence of [ 3 H] ryanodine binding using PKA-treated solubilized WT and V2475F channels. PKA phosphorylation did not change significantly the sensitivity of WT channels (EC 50 =6.4±0.14) but increased the already abnormal sensitivity of V2475F for cytosolic calcium (EC 50 =7.1±0.16, n=5). *P<0.05.
phosphorylation of V2475F channels, an almost obligatory condition during β-adrenergic stimulation of the heart, may be an exacerbating condition that favors uncontrollable Ca 2+ release in CPVT episodes.
V2475F Channels Display Abnormal Response to Luminal Ca 2+
A prevalent mechanism believed to trigger CPVT episodes is increased channel sensitivity to luminal Ca 2+ . 3 Recombinant WT and V2475F channels were reconstituted separately in planar lipid bilayers, and the sensitivity of the channel to luminal Ca 2+ was determined by clamping cis (cytosolic) Ca 2+ to low levels (pCa 7) and increasing Ca 2+ gradually in the trans (luminal) side of the channel. Figure 3A describes the sequential steps followed to generate the P o vs [Ca 2+ ] luminal plot of Figure 3B . For each [Ca 2+ ] luminal tested, we recorded at least 2 minutes of continuous activity per channel. In WT and V2475F channels, an increase in [Ca 2+ ] luminal produced an increase in P o , but the effect was more dramatic in the mutant channels ( Figure 3B ). Mean open time (τ open ) was the main factor driving the increase in P o for both groups of channels ( Figure 3C channels and producing a biphasic response in WT channels ( Figure 3D ). Thus, the negligible modification of τ close and the extraordinary prolongation of τ open by [Ca 2+ ] luminal are outstanding characteristics of the V2475F mutation.
Generation of RyR2-V2475F Knock-In Mice
We generated a knock-in mouse line harboring the RyR2-V2475F mutation. Figure 4A shows the strategy used to generate the targeting vector and the resultant targeted allele. Figure 4B and 4C show Southern blots and polymerase chain reaction that yield the expected amplification products. Figure 4D shows that mice heterozygous for the mutation (RyR2-V2475F −/+ ) have no gross anatomic or histological cardiac alterations, as expected, from the clinical presentation of CPVT in humans. Furthermore, functional echocardiographic data (heart rate, ejection fraction, left ventricle developed pressure) are normal for RyR2-V2475F −/+ mice, resembling the clinical data ( Figure  4E and 4F, and Online Table I ). However, heterozygotes propagate in a non-Mendelian fashion, generating offspring that are ≈20% WT and ≈80% heterozygotes ( Figure 4G ). We were unable to detect homozygous embryos as early as 9 days of gestation. Therefore, although mice heterozygous for the mutation have no gross functional or structural alterations under basal conditions, the V2475F mutation appears too severe to be harbored in both alleles. Correspondingly, there are no known cases of CPVT patients homozygous for a given mutation, and thus the heterozygous mice serve as excellent models to study this syndrome. The generation of the RyR2-V2475F −/+ mice provided an excellent opportunity to study the effect of the mutation in a native environment. Figure 5A shows aggregate data (P o ) from single-channel recordings using purified recombinant WT channels (RyR2-WT), recombinant V2475F (RyR2-V2475F), and RyR2 channels obtained from cardiac SR of RyR2-V2475F −/+ mice (Het mice). Each bar represents an independent channel, and all channels were recorded in the presence of 100 nmol/L cytosolic [Ca 2+ ] and 1 mmol/L [Ca 2+ ] luminal to maximize the phenotypic differences between WT and V2475F channels in their response to luminal Ca 2+ . As expected from the results of Figures 1 and 3 , WT channels displayed a modest response to luminal Ca 2+ , which yielded low P o (mean P o =0.06±0.02; n=11; Figure 5 ). V2475F channels, however, displayed a dramatic increase in P o mainly because of an increase in τ open , which yielded P o =0.29±0.08 (n=10). In contrast, RyR2 channels from RyR2-V2475F −/+ mice displayed widely variable P o ( Figure 5B ). Of the 10 recorded channels, 3 had the signature effect of the V2475F mutation (prolonged τ open ), which accounted for their high P o . Thus, there is variability in channel activity that we suggest is attributed to the heterogeneous nature of the channel subunits contributing to the tetrameric RyR2 channel (Online Figure V ).
Proarrhythmic Behavior in Ventricular Myocytes From V2475F −/+ Mice
With the molecular phenotype displayed by V2475F −/+ mice in single-channel experiments ( Figure 5 ), it was of interest to test whether their ventricular myocytes showed alterations in their intracellular Ca 2+ signaling. Cells were subjected to a stress test to assess their capacity to handle SR Ca 2+ load. Fluo-4-loaded ventricular myocytes were constantly perfused with Tyrode solution supplemented with isoproterenol and then field-stimulated at 1 Hz during 5 seconds to load the SR with Ca 2+ . After stimulation, cells were rested and constantly monitored to measure spontaneous Ca 2+ release (SCR) events. Figure 6A shows representative examples of line-scan images (length vs time) of WT and V2475F −/+ cells subjected to the stress protocol. V2475F +/− cells subjected to this protocol had more SCRs, either partial or fully propagated ( Figure 6A ). To determine the SR load at which SCR first occurs, WT or V2475F −/+ cardiomyocytes were perfused with Tyrode solution and paced at 0.3 Hz for 30 seconds. Caffeine (10 mmol/L) was then applied to measure basal SR load. Cells were then perfused with 100 nmol/L isoproterenol and continuously paced to gradually reload the SR. This gradual reloading of the SR with Ca 2+ is reflected in the amplitude of the [Ca 2+ ] i transient ( Figure 6B ), which is low immediately after caffeine and then increases as Ca 2+ entry through L-type Ca 2+ channels (I Ca ) fills the SR. To determine the SR load at which SCR occurs, a second caffeine pulse was applied immediately after the appearance of the first SCR. Under these conditions, the amplitude of this second caffeine-induced Ca 2+ transient closely approximated the SR load threshold for SCR. The aggregate data for 25 cells are shown in Figure 6C . Basal SR load was not significantly different between WT and V2475F −/+ cells. However, the incidence (frequency) of SCR is higher in V2475F −/+ cells ( Figure 6C , middle bars). Finally, the normalized SR load at which SCR first occurs is marginally higher in V2475F −/+ cells (0.74 for WT and 0.89 for V2475F −/+ of the caffeine-induced Ca 2+ release; P=0.05).
As a result of the possibility that residual Ca 2+ and caffeine from the first caffeine-evoked Ca 2+ transient affected the estimation of the threshold for SCR, we performed an independent test using HEK293 cells transfected with WT and V2475F channels. In this system, the main determinant of store overload-induced Ca 2+ release (SOICR) is assumed to be the intrinsic channel's sensitivity for luminal Ca 2+ . 5 Online Figure III shows a similar threshold for SOICR between WT-expressing and V2475F-expressing cells. These results suggest that increased sensitivity to [Ca 2+ ] luminal in single RyR2-V2475F channels does not manifest as a decrease in the threshold for SCR.
Arrhythmic Behavior in Whole Hearts and in Intact V2475F −/+ Mice
Having demonstrated that V2475F −/+ cardiomyocytes display a proarrhythmic substrate in the form of higher frequency of SCR, we next tested whether whole hearts from the same mice showed propensity for development of arrhythmias under βadrenergic stimulation. We performed experiments in freshly explanted hearts from V2475F −/+ mice using the Langendorff system and with simultaneous recording of electrograms, left ventricular pressure, temperature, and coronary flow. Figures 7A (WT) and 7B (V2475F +/− ) show electrogram and left ventricular pressure. Hearts were paced at 400 to 600 bpm with an electrode placed in the apex. In the WT group, perfusion with Tyrode solution supplemented with 1 µmol/L isoproterenol increased left ventricular pressure as expected and had no significant arrhythmic behavior. In contrast, the same maneuver performed in V2475F −/+ hearts frequently produced arrhythmic episodes characterized by premature ventricular complexes ( Figure 7 ) and ventricular bigeminy (not shown). In extreme cases, we observed ventricular fibrillation ( Figure  7B ). The type of arrhythmia, incidence, and duration also were quantified by electrocardiography in anesthetized WT and V2475F −/+ mice after intraperitoneal injection of epinephrine (2 mg/kg) and caffeine (120 mg/kg) ( Figure 7C ). This cocktail had minimal effect on WT mice (6.5±2.4 and 2.2±0.6 nonsustained and sustained arrhythmias, respectively, during a 30-minute recording) but was highly arrhythmogenic in V2475F −/+ mice (59±28 and 14.8±6.0 nonsustained and sustained arrhythmias, respectively, during a 30-minute recording period). Most of the arrhythmias were identified as premature ventricular complexes, bigeminy, or tachyarrhythmias ( Figure 7C ). Bidirectional VT was not present in WT mice but present in 2 of 6 V2475F −/+ mice ( Figure 7C [VF-1] and 7D).
Optical Mapping Reveals Multiple Ventricular Foci of Arrhythmia
We mapped the anterior ventricular epicardium of V2475F −/+ and WT hearts. Two mutant and 2 WT hearts were perfused with 200 nmol/L isoproterenol (0.2 mg/mL) for 10 minutes. Afterward, the Ca 2+ concentration was doubled (from 1.8 to 3.6 mmol/L). A bolus of isoproterenol (0.2 mg/mL) plus caffeine (100 mmol/L) was applied 10 and 20 minutes later. Long-lasting arrhythmias (>1 minute) were elicited in both mutant hearts. One WT heart had no arrhythmias, and the second heart underwent a short episode of VT (10 seconds). The spontaneous arrhythmias that occurred in the mutant hearts included bigeminy, short bursts of nonsustained VT, and sustained polymorphic VT. Impulse propagation during polymorphic VT is described in more detail in Figure 8 .
Discussion
In this study, we used a multidisciplinary approach encompassing molecular, cellular, whole heart, and intact animal experiments to elucidate the mechanisms by which a novel RyR2 mutation, V2475F, causes RyR2 dysfunction, abnormal [Ca 2+ ] i handling, and ventricular tachyarrhythmias. The mutation distinguished itself among other normally silent CPVT mutations by displaying a strong phenotype even in the absence of exacerbating factors (Figure 1 ). Heterozygous mice (RyR2-V2475 +/− ) faithfully recapitulate the cardinal signs of CPVT, including normal functional echocardiogram and ECG at rest, as well as absence of structural cardiac abnormalities (Figure 4 ). However, when challenged with an arrhythmogenic cocktail that activates the β-adrenergic cascade, RyR2-V2475F +/− mice display a highly arrhythmogenic phenotype (Figures 7 and 8) .
Recombinant RyR2-V2474F Channels Exhibit 3 Different Functional Defects
To date, most CPVT mutations have been functionally segregated into distinct groups affecting luminal Ca 2+ sensitivity, 3, 5, 6 FKBP12.6 association, 7,8 interdomain interactions, 9, 10 or Ca 2+ -dependent inactivation. 11, 12 This categorization provides a clean operational sorting of CPVT mutations, but it appears counterintuitive based on the structural complexity of the RyR2 protein. Actually, it would appear logical that a given CPVT mutation affected >1 aspect of RyR2 regulation because multiple functional domains have been mapped to regions where each mutation falls. 17 Here, we present evidence that V2475F mutation affects cytosolic Ca 2+ sensitivity (Figure 1 ), PKA phosphorylation ( Figure 2) , and luminal Ca 2+ modulation (Figure 3 ), 3 modes of RyR2 regulation highly relevant during a CPVT episode. Multiple modes of dysfunctional Ca 2+ release for a single CPVT mutation has been suggested, 12, 15 but it has not been demonstrated. This is the first documented case of heterogeneous RyR2 dysfunction caused by a CPVT-associated mutation.
In simplified solutions containing Ca 2+ as the only relevant agonist of RyRs, recombinant RyR2-V2475F channels displayed an increased sensitivity to activation by cytosolic [Ca 2+ ] that was most conspicuous at pCa 7 (100 nmol/L [Ca 2+ ]; Figure 1 ). The increased Ca 2+ sensitivity of V2475F Figure 6 . Proarrhythmic behavior in ventricular myocytes from V2475F heterozygous mice. A, Confocal line-scan images of [Ca 2+ ] i dynamics in ventricular myocytes of wild-type (WT) and V2475F +/− hearts. Cells were constantly perfused with Tyrode solution supplemented with isoproterenol and then stimulated at 1 Hz during 5 seconds to load the sarcoplasmic reticulum (SR) with Ca 2+ . Cells were then rested and the latency and number of spontaneous calcium release (SCR) events measured ( Figure S6) . B, Protocol to measure SR load threshold for SCR in WT and V2475F cells. Please see text for details. C, Combined data from at least n=25 cells/genotype. *P≤0.05.
was noted in a range of [Ca 2+ ] sufficiently low (pCa 8-pCa 6) to safely ascertain the exclusive participation of cytosolic activation sites; luminal Ca 2+ sites require greater [Ca 2+ ] for activation (tens to hundreds of µmol/L; Figure 2 ). 2, 5, 6 Furthermore, V2475F channels activated by cytosolic pCa 7 without [Ca 2+ ] luminal displayed an increased frequency of openings without significant alteration of their τ close (Figure 1 ), suggesting that the mutation does not destabilize the channel's close state as proposed for other CPVT mutations. 7-10 Although other CPVT mutations have been shown to alter cytosolic Ca 2+ sensitivity, this phenotype becomes apparent only after PKA dissociation of FKBP12.6. 7, 8 In the case of V2475F, this is a defect intrinsic to the channel protein. At face value, this alteration portends significant diastolic Ca 2+ leak in intact cardiomyocytes and it is conceivable that it contributed to the embryonic lethality of the RyR2-V2475F homozygous mice.
Still, the most dramatic effect of the V2475F mutation was its remarkable hypersensitivity to luminal Ca 2+ activation ( Figure 3A) . The exaggerated response of V2475F channels to [Ca 2+ ] luminal essentially dwarfed the otherwise modest response displayed by WT channels (Figure 3B ). Because the number of openings was actually decreased in the V2475F channels with respect to WT in the luminal Ca 2+ titration curve ( Figure 3D ), this dysfunction is at variance with altered cytosolic Ca 2+ activation (Figure 1) and strongly suggests the participation of luminal Ca 2+ sites as determinants of this molecular phenotype. Also, we used purified RyR2 channels and, thus, the easiest explanation for this effect is that Ca 2+ acted directly on the RyR2 channel and not on accessory proteins, as postulated for some forms of luminal Ca modulation. 18 Therefore, an extraordinary luminal Ca 2+ -induced increase in τ open by direct interaction of Ca 2+ ions with the channel is the most distinctive phenotype of this mutation ( Figure 4A ). This signature effect was later used to estimate the approximate proportion of dysfunctional channels in heterozygous RyR2-V2475F +/− hearts. By definition, arrhythmic episodes in CPVT are triggered by sympathetic stimulation. We and others have previously shown that RyR2 channels are among the first proteins to undergo metabolic phosphorylation in hearts perfused with β-adrenergic agonists. 14, 19 A relevant question, therefore, is whether phosphorylation worsens the molecular phenotype of RyR2 channels harboring CPVT mutations. We found that PKA phosphorylation modestly but significantly increased the cytosolic Ca 2+ dependence of activation of V2475F, but not WT, channels ( Figure 2C ). Specific phospho-sites were differentially phosphorylated in V2475F channels, resulting in decreased Ser2808 phosphorylation and increased Ser2030 phosphorylation (both PKA sites). The CaMKII site Ser2814 was not differentially affected. Thus, although the functional role of each of these sites is still controversial, 19, 20 there was uneven efficacy of PKA on the distinct phospho-sites, and this likely contributed to intensify the molecular phenotype of RyR2-V2475F channels. This is a novel aspect of RyR2 modulation in CPVT mutations. In contrast, CaMKII phosphorylation was not differentially affected by the V2475F mutation (Online Figure I ).
Severe Arrhythmic Phenotype in Mice Harboring the V2475F Mutation
Given the strong molecular phenotype of V2475F channels, we expected a correspondingly severe phenotype in mice harboring this mutation. The mutation appears embryonic-lethal in homozygous mice ( Figure 4G ) and triggers life-threatening arrhythmias in heterozygous mice (RyR2-V2475F +/− ). However, given that the mutation confers RyR2 channels a gain of function at baseline (ie, in the absence of sympathetic stimulation; Figures 1 and 3) , it is surprising that RyR2-V2475F +/− hearts are functionally and structurally indistinguishable from WT under basal conditions. We believe that at least 2 factors restrict the effects of the mutation at baseline. First, if we assume that mutant and WT alleles contribute equally and randomly to the formation of a tetrameric channel, then up to ≈94% of RyR2s channels would be phenotypically altered in RyR2-V2475F +/− mice if only 1 subunit was necessary to confer the gain of function (dominant-positive mutation; Online Figure  V) . However, only ≈30% of RyR2-V2475F +/− channels reconstituted in lipid bilayers exhibited dramatically prolonged τ open in the presence of 1 mmol/L [Ca 2+ ] luminal ( Figure 5 ). This fact alone strongly suggests that multiple subunits are necessary to confer the phenotype, thus decreasing the incidence of abnormal channels in the heterozygous population. Second, ventricular myocytes have powerful autoregulatory mechanisms that control the activity of leaky RyR2s in the long-term: Eisner et al have shown that increasing RyR2 activity (by Ca 2+ sensitization, phosphorylation, etc) induces more Ca 2+ release in the first few beats, but this drives greater Ca 2+ extrusion by the sodium-calcium exchanger and progressively decreases SR load, reducing the Ca 2+ available for release in subsequent beats. Despite the reduced SR Ca 2+ content, intracellular [Ca 2+ ] transients remain relatively constant as a result of higher fractional release by the sensitized RyR2s, and a new steady-state is established in which Ca 2+ influx and efflux are rebalanced. 21 Thus, autoregulatory mechanisms can effectively preclude tonic hyperactivity of RyR2s, at least within a defined range of SR loads. In the RyR2-V2475F +/− mouse, the basal hyperactivity of the relatively small pool of abnormal channels may be controlled by this mechanism.
In β-adrenergic-stimulated ventricular myocytes, dysfunctional RyR2-V2475F +/− channels clearly contribute to increased propensity for SCR ( Figure 6A and 6C) , despite the autoregulatory mechanisms mentioned. Interestingly, the [Ca 2+ ] luminal necessary to provoke SCR is similar for V2475F +/− and WT cardiomyocytes ( Figure 6B) , and in HEK293 cells the threshold for SOICR was also similar for WT and RyR2-V2475F channels (Online Figure I) . These findings may appear counterintuitive given the increased P o of RyR2-V2475F as a function of [Ca 2+ ] luminal ( Figure 3B) , but it is possible that other processes such as cytosolic Ca 2+ sensitivity and phosphorylation (both of which are altered in V2475F channels) take precedence over luminal [Ca 2+ ] to determine the likelihood of SCR. Also, whereas most CPVT-linked mutations that display decreased threshold for SOICR also display dramatic decrease of their τ close (τ close =7-fold to 20-fold faster than WT), 5, 22 the V2475F mutation displays a τ close that is only ≈1.2-fold faster than WT at physiologically relevant [Ca 2+ ] (Online Figure II) , clearly a marginal alteration in the context of other CPVT mutations. If we make the reasonable assumptions that SOICR is a good surrogate for SCR and that τ close is a critical determinant of the stability of the channel's closed state, then we would then expect that mutations that decrease τ close also lower the threshold for SCR. This is not the case for the V2475F mutation. Thus, we find it unlikely that the arrhythmogenic Ca 2+ release in the RyR2-V2475F +/− cardiomyocytes is solely determined by their threshold for SCR. Instead, we believe that the increased sensitivity to luminal Ca 2+ , concomitantly with elevated cytosolic Ca 2+ sensitivity and RyR2 phosphorylation, all converge to fasten RyR2 restitution, thus shortening Ca 2+ release refractoriness and increasing the incidence of SCR. In support of this hypothesis, the latency for SCR, a direct index of RyR2 restitution, was substantially faster in RyR2-V2475F −/+ than WT cardiomyocytes (Online Figure VI) . The dissociation of [Ca 2+ ] luminal from SCR likelihood is not unprecedented: in a canine model of ventricular fibrillation, the increased rate of arrhythmogenic SCR was not determined by [Ca 2+ ] luminal ; instead, RyR2 oxidation and phosphorylation shortened RyR2 refractoriness. 23 In Langendorff-perfused hearts and in intact animals, β-adrenergic stimulation brings about discrete arrhythmic behavior in RyR2-V2475F +/− mice. The demonstration of tachyarrhythmias in normally arrhythmia-resilient mice 24 is especially remarkable and underscores the importance of RyR2 dysfunction as arrhythmogenic trigger. Optical mapping revealed the multifocal origin of such events (Figure 8 ), compatible with triggered activity at various myocardial layers. All these events suggest active participation of ventricular cells as generators of arrhythmias; however, bidirectional VT, a pathognomonic event of digitalis intoxication, 25 and CPVT, 26 which reflects alternating firing by the His-Purkinje system, 27 also were observed in intact mice. The remarkable electrocardiographic similarity across species caused by Ca 2+triggered arrhythmias suggests common pathways, regardless of the molecular mechanisms. Induction of delayed afterdepolarizations is possibly the converging point.
Conclusions
Experiments in vitro showed that RyR2 mutations linked to CPVT, arrhythmogenic right ventricular dysplasia, or hypertrophic cardiomyopathy each exhibit distinct molecular phenotypes. 12, 28, 29 Here, we demonstrate for the first time that a CPVT-linked mutation can simultaneously induce multiple molecular alterations in the RyR2 channel, yet can retain the distinctive traits of the disease at the whole heart and intact animal levels. Given that various regulatory regions potentially may be affected by a point mutation in the RyR2, we find it surprising that this variegated molecular dysfunction had not been detected before. We hypothesize that multidisciplinary screening strategies in a larger number of mutations will show even more complex mechanisms of CPVT. Unveiling these mechanisms is not merely an academic exercise but a task with relevant clinical implications. For example, it is plausible that the location and the mechanisms of arrhythmia determine the severity of the phenotype or condition the efficacy of antiarrhythmic drugs, especially those that directly target the RyR2. Thus, identifying the mutations and their mechanisms could serve as a valuable tool for risk stratification or therapy individualization in CPVT patients.
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